Resources
Discover Valuable Insights and Strategies
Explore our blog for expert advice, industry trends, and innovative strategies that empower your team and elevate your business
-4.png)
Featured
March 10, 2026
Nursing Home Litigation Playbook: Purpose-Built AI for Complex Cases
Nursing home litigation is among the most complex and document-intensive practice areas in plaintiff's law. The cases are large, the records are dense, the defendants are well-resourced, and the evidentiary chain — from a single care failure to a corporate accountability argument — spans months or years of institutional documentation. That complexity demands tools built to a higher standard than general-purpose AI can meet. Parambil is purpose-built for nursing home litigation, designed specifically for the record systems, regulatory data, and evidentiary demands of this practice area.
Streamlining MDL Censuses: How Parambil Al is Revolutionizing Court-Mandated Data Collection in Mass Tort Litigation
The landscape of mass tort litigation is rapidly evolving, and one of the most significant changes we're witnessing is the increasing frequency of court-mandated censuses at the very beginning of Multi District Litigation (MDL) proceedings. What was once an occasional requirement has now become standard practice, fundamentally changing how legal teams must approach case preparation and data management.
Our Annual Security Review: Why SOC 2, HIPAA Compliance, and Penetration Testing Matter
As we complete our yearly SOC 2 audit and penetration testing, we wanted to take a moment to discuss our approach to security, why these measures matter, and how they protect the sensitive data you entrust to us. In today's threat landscape, robust cybersecurity isn't just a technical requirement—it's fundamental to maintaining the trust and confidentiality that forms the foundation of our client relationships.
Don't Let Complex Plaintiff Fact Sheets Sink Your GLP-1 Cases: How AI Can Transform Your Weight Loss Litigation Practice
The weight loss drug litigation landscape has exploded with cases involving GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro. But there's a critical bottleneck preventing many firms from capitalizing on this lucrative area: the overwhelming complexity of plaintiff fact sheets (PFS).
Contact us
Connect with us
You can also use the feedback form below to reach out to us directly through our website.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.